Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

MDS 2023

The 17th International Congress on Myelodysplastic Syndromes

03–06 May 2023 | Marseille, France

VJHemOnc is pleased to be a Media Partner for the 17^th International Congress on Myelodysplastic Syndromes (MDS 2023) which took place in Marseille, France, on May 3-6, 2023. This meeting brought renowned experts together to discuss advances in basic and translational research in the field of MDS.

View all videos

Genetic mutations and inflammation: understanding the links and improving prognosis in MDS

Uwe Platzbecker • 11 May 2023

The potential of combining pyrimethamine with venetoclax in HMA-resistant MDS

Aditi Shastri • 4 May 2023

Validation of non-invasive AI diagnostic tool for MDS

Moshe Mittelman • 5 May 2023

MDS 2023 highlights: classification and risk stratification systems & progression from CH to MDS

Norbert Vey • 5 May 2023

Automated tool for MDS classification using the WHO & ICC classification systems

Rashmi Kanagal-Shamanna • 5 May 2023

The prognostic impact of IDH mutations and the role of IDH inhibitors in MDS

Eytan Stein • 5 May 2023

What can artificial intelligence bring to the diagnosis and management of MDS?

Matteo Della Porta • 27 Apr 2023

Challenges in distinguishing between pre-MDS states and MDS, and approaches to improve diagnosis

Klaus Metzeler • 5 May 2023

The efficacy of low-dose ASTX727 in low-risk MDS

Guillermo Garcia-Manero • 4 May 2023

Prognosis & advances in treatment strategies for SF3B1-mutant MDS

Michaela Fontenay • 5 May 2023

The role of antibody-based therapies in MDS treatment

Andrew Brunner • 4 May 2023

PevAz update: pevonedistat & azacitidine in R/R MDS and MDS/MPN after DNMTi failure

Michael Savona • 5 May 2023